Appendix 3B - Proposed issue of securitiesAppendix 3B - Proposed issue of securities1 / 5Announcement SummaryEntity nameCAMBIUM BIO LIMITEDAnnouncement TypeNew announcementDate of this announcement16/9/2026The Proposed issue is:Total number of +securities proposed to be issued for a placement or...
Proposed issue of securities - CMB
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- Notice of ceasing to be a substantial holder
- Change in Substantial Holding
- Update - Proposed issue of securities - CMB
- Notification regarding unquoted securities - CMB
- FY26 Appendix 4E and Annual Report
Later from Cambium Bio
- Cambium Bio Secures A$10.85 Million Funding Package
- Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
- Notification of cessation of securities - CMB
- Date of AGM and Closing Date for Director Nominations
- Corporate Presentation - September 2026
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio